Danish Crown to cease operations at China unit
The plant, which opened in 2019 and is located near Shanghai, was put up for sale by the company last month.
In a statement, Danish Crown said the factory has not reached the 'intended profitability' due to 'ongoing challenges'. Attempts to address the issue have been 'unsuccessful', it added.
Danish Crown CFO Anders Aakær Jensen said: 'It is clear to us that the operations in Pinghu is not the right strategic fit for Danish Crown.
'To carry on our current set-up in Pinghu is no longer a viable option, and therefore we have decided that the time is right to bring those operations to an end while we work diligently to reach a final decision about the future of the factory itself.'
Jensen confirmed the meat co-operative has signed a letter of intent with a 'preferred buyer and agreed terms for a divestment'.
'While these talks are promising, we expect they will still take a few months to conclude,' Jensen added.
The pork giant said the end of operations in Pinghu could result in 112 redundancies.
The company intends to 'repurpose the quality equipment' from the site elsewhere in its global supply chain.
Danish Crown has a casings business, DAT-Schaub, with operations in China that will continue.
"The closure and sale of the factory in Pinghu will have a minor effect on our business in China," a Danish Crown spokesperson told Just Food. "In the financial year 2023/24 we had a turnover in China of DKr2.8bn ($390.4m), mostly from the export of Danish pork meat to China. We expect a turnover at the same level this financial year."
Last month, Danish Crown announced it had decided to stop selling retail-packed fresh meat in Germany as part of efforts to improve its profitability.
The decision will lead to the winding down of the Oldenburg Convenience division in Oldenburg in north-west Germany by the end of February.
"Danish Crown to cease operations at China unit" was originally created and published by Just Food, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
a day ago
- Wall Street Journal
U.S. Treasury Yields Rise as Risk Appetite Dims Demand
1039 GMT – U.S. Treasury yields rise in midday European trade, as better risk appetite takes a toll. 'Risk appetite could be fueled by positive developments around trade negotiations and could weigh on bonds,' Excess' Dat Tong says in a note. 'In this regard, yields could react to any developments or setbacks in trade negotiations,' the senior financial markets strategist says. In the most recent development, the U.S. and Japan agreed on a trade deal, with President Trump confirming a 15% tariff on Japanese exports. The two-year Treasury yield is up by 2 basis points at 3.849%, while and the 10-year yield rises 3.8 basis points to 4.373%, according to Tradeweb. ( 0754 GMT – Yields on U.K. government bonds rise, tracking similar moves in global sovereign bond yields after a poor performance at an auction of 40-year Japanese government bonds. The 40-year Japanese bond yielded 3.375% at the auction, the highest level on record, and had the weakest demand since 2011, driving all Japanese government bond yields higher, Deutsche Bank Research analysts say in a note. The rise has cascaded across global sovereign bond markets, the analysts say. Ten-year U.K. government bond yields climb 4 basis points to last trade at 4.612%, Tradeweb data show. (
Axios
3 days ago
- Axios
Biogen plans to invest $2B into its RTP manufacturing facilities
Biogen, one of the world's largest biotechnology companies, plans to invest $2 billion and build a new manufacturing facility in Research Triangle Park. Why it matters: Biogen is one of RTP's largest employers with more than 1,500 workers in Durham County. The latest investment will help it expand its manufacturing capabilities in North Carolina. Between the lines: Investment into pharmaceutical and biotech manufacturing remains on fire in the Triangle, with Biogen representing just the latest in a string of jobs announcements. The biotechnology company Genentech said earlier this year it plans to add 400 jobs in Holly Springs, and Amgen and Fujifilm Diosynth recently completed manufacturing facilities there as well. Last year, Novo Nordisk, the Danish maker of drugs like Ozempic, announced a planned $4 billion investment in facilities in Johnston County. Zoom in: The investment will help the drug maker build its eighth manufacturing facility in North Carolina, Biogen said in a statement. The company makes a variety of treatments, including for multiple sclerosis, and has a pipeline of products being tested for Alzheimer's, Parkinson's and other diseases. The company declined an interview request, and it was unclear how many jobs could be supported at the new facility. In 2023, the company laid off some workers due to the bumpy launch of an Alzheimer's treatment, Fierce Biotech reported. The big picture: The Triangle, which the real estate services firm JLL pegs as the fourth-largest life sciences market in the country, has a lower vacancy rate than its larger peers for life science space. That's primarily due to a combination of the region not building as much as markets like Boston and San Diego since the pandemic, plus a number of biomanufacturing wins, according to Eric Forshee, JLL's executive vice president for life sciences at its Raleigh office. "North Carolina, especially on the biomanufacturing side, has good affordable land, quality sites, great talent and good incentives," Forshee told Axios. What's next: Reuters noted that Biogen is one of several drug makers that have announced investments amid the threat of a 200% tariff on imported drugs from the Trump administration, though Biogen's announcement made no mention of tariffs. It remains to be seen how tariffs could help or hinder biomanufacturing in the Triangle.
Business Insider
4 days ago
- Business Insider
Hims Stock at $50: Here's What Truist Expects Next
Hims & Hers Health (NYSE:HIMS) stock has had a curious run in 2025. The first half of the year was marked by a massive 35% single-day plunge, sparked by Novo Nordisk's sudden decision to cut ties with the telehealth company. The Danish drugmaker accused Hims & Hers of engaging in misleading marketing and distributing unauthorized compounded versions of its blockbuster weight-loss drug, Wegovy. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Despite the controversy, the stock has staged an impressive rebound, with shares up 108% year-to-date and now hovering around $50. The rally has been driven by strong quarterly results and growing momentum in the company's weight-loss offerings. Looking ahead, all eyes now turn to the company's upcoming Q2 earnings report, slated for August 4. Truist analyst Jailendra Singh expects results to land mostly in line with expectations, noting that current forecasts already reflect the high end of HIMS' guidance. He projects revenue of $549.4 million and adjusted EBITDA of $74.4 million, closely aligned with Street consensus and the company's provided range. However, Singh also flags some cautionary signals. The analyst anticipates a slight dip in online revenue per subscriber compared to Q1, attributing it to seasonal trends and reduced reliance on commercially available Semaglutide. Q1's outperformance, after all, benefited from one-off drivers like the Super Bowl ad and the initial buzz around HIMS-branded weight-loss offerings. That brings up the bigger question: where does HIMS go from here in the second half of the year? While some investors worry about a potential guidance cut following the Novo fallout, others are optimistic about a lift tied to the recent acquisition of European telemedicine provider Zava. Singh, for his part, remains cautious. The analyst believes a 2H ramp may be difficult unless Zava or other acquisitions begin to meaningfully contribute. Still, he doesn't expect management to revise guidance just yet, preferring to wait and assess the impact of new initiatives in Q3. As for upcoming developments to watch, Singh cites updates on a possible lawsuit from Novo Nordisk (which would be negative), new product launches in testosterone and menopause treatments (positive), and further M&A activity (also positive). 'From additional M&A point of view, a transaction giving the company entry into the employer/payor market will be transformational and has potential to change the narrative,' Singh further said. What to Do with HIMS Stock Now? Singh is sticking with a Hold (i.e., Neutral) rating, nudging his price target up from $45 to $48, which still suggests ~5% downside from where the stock is currently trading. (To watch Singh's track record, click here) And he's not alone in that cautious stance. The broader analyst community is mostly on the sidelines too, with 7 Holds, 2 Sells, and just 1 Buy – all coalescing to a Hold consensus rating. Based on the average price target of $41.78, the Street sees the stock pulling back by 17% over the next year. (See HIMS stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
